At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 72 enrolled
Drug / intervention
PF-03084014drug
Likely dose
PF-03084014 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE I TRIAL OF PF-03084014 IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCY AND T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA
In Brief
A Phase 1 clinical trial evaluating PF-03084014 for Neoplasms by Histologic Type. Completed, enrolled 72 participants across 10 sites in 2 countries.
Detailed Summary
This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms by Histologic Type
CountriesItaly, United States
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2009
Enrollment StartJun 2009
Primary CompletionJan 2013
Study CompletionNov 2016
TodayJul 2026
First PostedApr 8, 2009
Enrollment StartJun 25, 2009
Primary CompletionJan 10, 2013
Study CompletionNov 22, 2016
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 17.2 years ago
Interventions
PF-03084014drug
10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily